Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?

There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinder, Markus, Yi, B. Alexander, Langenickel, Thomas H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947521/
https://www.ncbi.nlm.nih.gov/pubmed/29315510
http://dx.doi.org/10.1002/cpt.1010
_version_ 1783322385457348608
author Hinder, Markus
Yi, B. Alexander
Langenickel, Thomas H.
author_facet Hinder, Markus
Yi, B. Alexander
Langenickel, Thomas H.
author_sort Hinder, Markus
collection PubMed
description There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions.
format Online
Article
Text
id pubmed-5947521
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59475212018-05-17 Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials? Hinder, Markus Yi, B. Alexander Langenickel, Thomas H. Clin Pharmacol Ther Reviews There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions. John Wiley and Sons Inc. 2018-02-01 2018-05 /pmc/articles/PMC5947521/ /pubmed/29315510 http://dx.doi.org/10.1002/cpt.1010 Text en © 2018 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Hinder, Markus
Yi, B. Alexander
Langenickel, Thomas H.
Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
title Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
title_full Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
title_fullStr Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
title_full_unstemmed Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
title_short Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
title_sort developing drugs for heart failure with reduced ejection fraction: what have we learned from clinical trials?
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947521/
https://www.ncbi.nlm.nih.gov/pubmed/29315510
http://dx.doi.org/10.1002/cpt.1010
work_keys_str_mv AT hindermarkus developingdrugsforheartfailurewithreducedejectionfractionwhathavewelearnedfromclinicaltrials
AT yibalexander developingdrugsforheartfailurewithreducedejectionfractionwhathavewelearnedfromclinicaltrials
AT langenickelthomash developingdrugsforheartfailurewithreducedejectionfractionwhathavewelearnedfromclinicaltrials

Ejemplares similares